Wall Street Zen upgraded shares of Aspen Neuroscience (NASDAQ:ASPE – Free Report) to a hold rating in a research report released on Saturday,Wall Street Zen reports.
Aspen Neuroscience Stock Performance
ASPE stock traded down $1.02 during midday trading on Friday, hitting $12.59. The stock had a trading volume of 173,575 shares, compared to its average volume of 428,389. Aspen Neuroscience has a 1-year low of $11.20 and a 1-year high of $14.90.
Insider Transactions at Aspen Neuroscience
In other Aspen Neuroscience news, major shareholder Venture Fund X. L.P. Arch bought 1,200,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were bought at an average price of $15.00 per share, for a total transaction of $18,000,000.00. Following the transaction, the insider directly owned 1,200,000 shares in the company, valued at approximately $18,000,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Orbimed Advisors Llc bought 1,000,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were acquired at an average cost of $15.00 per share, with a total value of $15,000,000.00. Following the purchase, the director directly owned 3,589,132 shares of the company’s stock, valued at $53,836,980. This trade represents a 38.62% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 3,333,333 shares of company stock valued at $49,999,995.
Aspen Neuroscience Company Profile
Aspen Neuroscience, Inc. is a biotechnology company focused on developing regenerative medicine therapies for neurological disorders. The company’s approach uses a patient’s own cells to create induced pluripotent stem cells, which are then differentiated into specialized cells intended to replace damaged or lost tissue. Aspen’s lead program, ANPD001, is designed as a potential cell replacement therapy for Parkinson’s disease. The company has also developed genetic screening and manufacturing processes intended to evaluate a patient’s cells and produce an individualized therapeutic product.
Further Reading
- Five stocks we like better than Aspen Neuroscience
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Aspen Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
